Clinical Trial: New Inhibitor Tested for Patients With Relapsed or Refractory Multiple Myeloma
Posted: Aug 09, 2018
Clinical Trial:  New Inhibitor Tested for Patients With Relapsed or Refractory Multiple Myeloma image

A phase I clinical trial is open testing AMG 176 in patients with relapsed or refractory multiple myeloma (as well as patients with acute myeloid leukemia).  AMG 176 is an MCL-1 inhibitor (myeloid cell leukemia-1) that can prevent cancer cells from creating proteins to protect itself, and can cause cell death. The protein encoded by the MCL-1 gene belongs to the Bcl-2 family.

It is the first time this experimental drug is being given to humans. It is open-label, non-randomized, and will be available at multiple cancer centers across the country.

  • Open-Label: Patients and their doctors will know both the treatment and the dose that they will be receiving.
  • Dose Escalation: The amount of the study drug is periodically increased to determinethe maximum tolerated dose (MTD) to be used in future trials.

It is anticipated that 100 patients will join this study to explore dosing of AMG 176 (intravenously) in four different cohorts (or groups). Patients must have relapsed or refractory myeloma, with at least 2 lines of therapy, and satisfactory hematological function without transfusion or growth factor support.

Click here to learn more about this study and see if you may be eligible. You can also call SparkCures with any questions at (888) 828-2206.

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Bristol Myers Squibb
Abbvie
Genentech
GSK
Janssen Oncology

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation for Multiple Myeloma (formerly know as Myeloma Crowd) is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811